Why the study?
Does pimobendan improve hemodynamic parameters in animal models of normal and depressed myocardial function?
Does pimobendan improve hemodynamic parameters in animal models of normal and depressed myocardial function?
Pimobendan demonstrates potent positive inotropic and vasodilatory effects in animal models, suggesting potential utility in the treatment of congestive heart failure.
Answers are grounded in this paper and cite their sources.
Pimobendan improves hemodynamics in canine heart failure models; hypothesis-generating and should not yet influence human practice.
Pimobendan (UD-CCi 1 15 BS) is a potent positive inotropie agent with vasodilatory properties. This he-modynamie profile was demonstrated in conscious rabbits chronically instrumented with Doppler flow probes. Pimobendan (10. 30. 100. and 300 μg/kg i.v.) increased cardiac output, stroke volume, heart rate, and mesenteric, renal, and hindquarter blood flow velocities, and decreased diastolic blood pressure. The positive inotropic effects of pimobendan and its effects on pre- and afterload were also shown in dogs with propranolol-induced depressed myocardial function. Pimobendan exhibited strong effects on stroke volume (up to 59%) and pulmonary capillary wedge pressure (up to –84‘’;). The substance increased left ventricular (LV) dp/dimax up to 150% and also had favorable effects on renal blood flow. Left ventricular function curves showed the usefulness of pimobendan in this acute heart failure model. Pimobendan is well absorbed and its duration of action is long. Positive inotropic effects of pimobendan were observed for 8–12 h after oral administration of 0.1–1 mg/kg to conscious dogs. It is concluded that pimobendan produces cardiovascular effects that may be useful in the treatment of congestive heart failure
No takes yet. Share an insight, caveat, or question.
Meel et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: